| Ghassan Merrawi, RPH | |
|
15010 W Whitesbridge Ave, Kerman, CA 93630-1030 | |
| (559) 400-8883 | |
| Not Available |
| Full Name | Ghassan Merrawi |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 15010 W Whitesbridge Ave, Kerman, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386142669 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 78178 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ghassan Merrawi, RPH 15010 W Whitesbridge Ave, Kerman, CA 93630-1030 Ph: (559) 400-8883 | Ghassan Merrawi, RPH 15010 W Whitesbridge Ave, Kerman, CA 93630-1030 Ph: (559) 400-8883 |
News Archive
The Guardian examines a new Millennium Villages Project (MVP) - "the integrated approach to rural development spearheaded by Jeffrey Sachs of Columbia University's Earth Institute" - that was launched last week in northern Uganda "by Ghana's new president John Dramani Mahama and U.K. international development secretary Andrew Mitchell."
BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the launch of the first automated phenotypic test to detect and classify carbapenemase-producing organisms (CPO).
Newborn babies who are diagnosed with and treated for jaundice are no more likely than other babies to suffer long-term developmental problems, according to a study published in the New England Journal of Medicine.
Patients who underwent endoscopic testing prior to surgery for lung cancer had significantly better quality of life at the end of the staging process, with no significant difference in costs between the two strategies, according to data presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
› Verified 3 days ago
Dat Nguyen, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 14061 W Whitesbridge Ave, Kerman, CA 93630 Phone: 559-846-1200 | |
Na Young Lee, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 14967 W Whitesbridge Ave, Kerman, CA 93630 Phone: 559-842-0030 | |
Dennis Elek, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 456 S Madera Ave, Kerman, CA 93630 Phone: 559-846-7115 Fax: 559-846-9756 | |
Daniel Emenike Ogbuehi, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 456 S Madera Ave, Kerman, CA 93630 Phone: 559-846-7115 | |
Natalie Ng, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 456 S Madera Ave, Kerman, CA 93630 Phone: 559-846-7115 Fax: 559-846-9756 | |
Dr. Tony Nguyen, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 14061 W Whitesbridge Ave, Kerman, CA 93630 Phone: 559-846-1209 | |
Nekeitha Lyn Mccauley, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 456 S Madera Ave, Kerman, CA 93630 Phone: 559-846-7115 |